使用新型CORE风险评分预测普通人群10年肝硬化风险:基于人群的队列研究
在瑞典480 651名无已知肝病史的初级保健或职业健康筛查人群中开发并外部验证CORE风险模型,用于预测10年主要不良肝脏结局(MALO)。CORE模型纳入年龄、性别、天冬氨酸氨基转移酶、丙氨酸氨基转移酶和γ-谷氨酰转移酶。CORE的10年AUC为88%(95%CI 87%至89%),优于FIB-4的79%(78%至80%),校准良好,在所有风险阈值下净获益均高于FIB-4。
要点
- CORE模型仅使用年龄、性别及三项常规肝酶指标预测10年MALO风险。
- CORE的10年AUC为88%(95%CI 87%至89%),FIB-4为79%(78%至80%)。
- CORE在所有风险阈值下净获益均高于FIB-4,校准在三个队列中均良好。
核心结论
- CORE模型基于灵活建模方法并使用初级保健中易获取的生物标志物,在预测普通人群肝脏相关结局方面优于FIB-4,可能成为普通人群肝病风险分层的新手段。
研究设计与样本
- 基于人群的队列研究,在瑞典480 651名无已知肝病史且接受初级保健或职业健康筛查血液检测的个体中开发模型,并在芬兰和英国两个队列(24 191人和449 806人)中验证。
- 使用灵活参数生存模型构建风险模型,纳入年龄、性别、天冬氨酸氨基转移酶、丙氨酸氨基转移酶和γ-谷氨酰转移酶。
- 通过时间依赖AUC评估区分度,校准曲线评估校准度,决策曲线分析评估临床效用,并与FIB-4评分比较。
主要发现
- 中位随访时间为28年,期间观察到7168例MALO事件;10年MALO发生风险为0.27%。
- CORE的10年AUC为88%(95%CI 87%至89%),FIB-4为79%(78%至80%)。
- CORE在三个队列中校准均良好,决策曲线分析显示CORE在所有风险阈值下净获益均高于FIB-4。
关键数值与推荐
- MALO定义为代偿性和失代偿性肝硬化、肝细胞癌、肝移植及肝相关死亡的复合结局。
- CORE模型包含年龄、性别、天冬氨酸氨基转移酶、丙氨酸氨基转移酶和γ-谷氨酰转移酶。
- CORE的10年AUC为88%(95%CI 87%至89%),FIB-4为79%(78%至80%)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and validate a novel risk prediction model for incident major adverse liver outcomes (MALO) in a primary care setting. DESIGN: Population based cohort study. SETTING: Sweden, with validation in Finland and the UK. PARTICIPANTS: Model development in 480 651 individuals with no known history of liver disease and blood tests taken in primary care or at occupational healthcare screenings; validation in two cohorts with 24 191 and 449 806 individuals without known history of liver disease. MAIN OUTCOME MEASURES: 10 year risk of a composite outcome of compensated and decompensated cirrhosis, hepatocellular carcinoma, liver transplant, and liver related mortality, collectively referred to as MALO. RESULTS: A new risk model was created using flexible parametric survival models and several easily available laboratory based biomarkers. The model includes age, sex, aspartate aminotransferase, alanine aminotransferase, and γ-glutamyl transferase. The model's performance was assessed in terms of discrimination (time dependent area under the curve), calibration (calibration curves), and clinical utility (decision curve analysis). External validation was done using data from the UK Biobank and the FINRISK and Health 2000 cohorts and compared with the FIB-4 score. The median follow-up time was 28 years, and 7168 MALO events were observed in that time. The incident risk of MALO at 10 years was 0.27%. The new risk score, termed CORE (Cirrhosis Outcome Risk Estimator), achieved a 10 year area under the curve of 88% (95% confidence interval 87% to 89%) compared with 79% (78% to 80%) for FIB-4. The calibration of CORE was good in all three cohorts, and according to the decision curve analysis CORE provides a higher net benefit than FIB-4 for all risk thresholds. CONCLUSIONS: The CORE model, based on a flexible modelling approach and using biomarkers easily accessible in primary care, outperforms FIB-4 when predicting liver related outcomes in the general population and could be a novel means to stratify patients at risk for liver disease in the general population.
引用
- Strandberg R, Åberg F, Asteljoki JV, et al. Use of new CORE risk score to predict 10 year risk of liver cirrhosis in general population: population based cohort study. BMJ. 2025. PMID: 41022462. doi:10.1136/bmj-2024-083182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。